Cargando…

Sex-based clinical and immunological differences in COVID-19

BACKGROUND: Males and females differ in their immunological responses to foreign pathogens. However, most of the current COVID-19 clinical practices and trials do not take the sex factor into consideration. METHODS: We performed a sex-based comparative analysis for the clinical outcomes, peripheral...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Bin, Cai, Yun, Li, Ning, Li, Kening, Wang, Zhihua, Li, Lu, Wu, Lingxiang, Zhu, Mengyan, Li, Jie, Wang, Ziyu, Wu, Min, Li, Wanlin, Wu, Wei, Zhang, Lishen, Xia, Xinyi, Wang, Shukui, Chen, Hongshan, Wang, Qianghu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256650/
https://www.ncbi.nlm.nih.gov/pubmed/34225644
http://dx.doi.org/10.1186/s12879-021-06313-2
_version_ 1783718140628172800
author Huang, Bin
Cai, Yun
Li, Ning
Li, Kening
Wang, Zhihua
Li, Lu
Wu, Lingxiang
Zhu, Mengyan
Li, Jie
Wang, Ziyu
Wu, Min
Li, Wanlin
Wu, Wei
Zhang, Lishen
Xia, Xinyi
Wang, Shukui
Chen, Hongshan
Wang, Qianghu
author_facet Huang, Bin
Cai, Yun
Li, Ning
Li, Kening
Wang, Zhihua
Li, Lu
Wu, Lingxiang
Zhu, Mengyan
Li, Jie
Wang, Ziyu
Wu, Min
Li, Wanlin
Wu, Wei
Zhang, Lishen
Xia, Xinyi
Wang, Shukui
Chen, Hongshan
Wang, Qianghu
author_sort Huang, Bin
collection PubMed
description BACKGROUND: Males and females differ in their immunological responses to foreign pathogens. However, most of the current COVID-19 clinical practices and trials do not take the sex factor into consideration. METHODS: We performed a sex-based comparative analysis for the clinical outcomes, peripheral immune cells, and severe acute respiratory syndrome coronavirus (SARS-CoV-2) specific antibody levels of 1558 males and 1499 females COVID-19 patients from a single center. The lymphocyte subgroups were measured by Flow cytometry. The total antibody, Spike protein (S)-, receptor binding domain (RBD)-, and nucleoprotein (N)- specific IgM and IgG levels were measured by chemiluminescence. RESULTS: We found that male patients had approximately two-fold rates of ICU admission (4.7% vs. 2.7% in males and females, respectively, P = 0.005) and mortality (3% vs. 1.4%, in males and females, respectively, P = 0.004) than female patients. Survival analysis revealed that the male sex is an independent risk factor for death from COVID-19 (adjusted hazard ratio [HR] = 2.22, 95% confidence interval [CI]: 1.3–3.6, P = 0.003). The level of inflammatory cytokines in peripheral blood was higher in males during hospitalization. The renal (102/1588 [6.5%] vs. 63/1499 [4.2%], in males and females, respectively, P = 0.002) and hepatic abnormality (650/1588 [40.9%] vs. 475/1499 [31.7%], P = 0.003) were more common in male patients than in female patients. By analyzing dynamic changes of lymphocyte subsets after symptom onset, we found that the percentage of CD19+ B cells and CD4+ T cells was generally higher in female patients during the disease course of COVID-19. Notably, the protective RBD-specific IgG against SARS-CoV-2 sharply increased and reached a peak in the fourth week after symptom onset in female patients, while gradually increased and reached a peak in the seventh week after symptom onset in male patients. CONCLUSIONS: Males had an unfavorable prognosis, higher inflammation, a lower percentage of lymphocytes, and indolent antibody responses during SARS-CoV-2 infection and recovery. Early medical intervention and close monitoring are important, especially for male COVID-19 patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-021-06313-2.
format Online
Article
Text
id pubmed-8256650
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-82566502021-07-06 Sex-based clinical and immunological differences in COVID-19 Huang, Bin Cai, Yun Li, Ning Li, Kening Wang, Zhihua Li, Lu Wu, Lingxiang Zhu, Mengyan Li, Jie Wang, Ziyu Wu, Min Li, Wanlin Wu, Wei Zhang, Lishen Xia, Xinyi Wang, Shukui Chen, Hongshan Wang, Qianghu BMC Infect Dis Research Article BACKGROUND: Males and females differ in their immunological responses to foreign pathogens. However, most of the current COVID-19 clinical practices and trials do not take the sex factor into consideration. METHODS: We performed a sex-based comparative analysis for the clinical outcomes, peripheral immune cells, and severe acute respiratory syndrome coronavirus (SARS-CoV-2) specific antibody levels of 1558 males and 1499 females COVID-19 patients from a single center. The lymphocyte subgroups were measured by Flow cytometry. The total antibody, Spike protein (S)-, receptor binding domain (RBD)-, and nucleoprotein (N)- specific IgM and IgG levels were measured by chemiluminescence. RESULTS: We found that male patients had approximately two-fold rates of ICU admission (4.7% vs. 2.7% in males and females, respectively, P = 0.005) and mortality (3% vs. 1.4%, in males and females, respectively, P = 0.004) than female patients. Survival analysis revealed that the male sex is an independent risk factor for death from COVID-19 (adjusted hazard ratio [HR] = 2.22, 95% confidence interval [CI]: 1.3–3.6, P = 0.003). The level of inflammatory cytokines in peripheral blood was higher in males during hospitalization. The renal (102/1588 [6.5%] vs. 63/1499 [4.2%], in males and females, respectively, P = 0.002) and hepatic abnormality (650/1588 [40.9%] vs. 475/1499 [31.7%], P = 0.003) were more common in male patients than in female patients. By analyzing dynamic changes of lymphocyte subsets after symptom onset, we found that the percentage of CD19+ B cells and CD4+ T cells was generally higher in female patients during the disease course of COVID-19. Notably, the protective RBD-specific IgG against SARS-CoV-2 sharply increased and reached a peak in the fourth week after symptom onset in female patients, while gradually increased and reached a peak in the seventh week after symptom onset in male patients. CONCLUSIONS: Males had an unfavorable prognosis, higher inflammation, a lower percentage of lymphocytes, and indolent antibody responses during SARS-CoV-2 infection and recovery. Early medical intervention and close monitoring are important, especially for male COVID-19 patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-021-06313-2. BioMed Central 2021-07-05 /pmc/articles/PMC8256650/ /pubmed/34225644 http://dx.doi.org/10.1186/s12879-021-06313-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Huang, Bin
Cai, Yun
Li, Ning
Li, Kening
Wang, Zhihua
Li, Lu
Wu, Lingxiang
Zhu, Mengyan
Li, Jie
Wang, Ziyu
Wu, Min
Li, Wanlin
Wu, Wei
Zhang, Lishen
Xia, Xinyi
Wang, Shukui
Chen, Hongshan
Wang, Qianghu
Sex-based clinical and immunological differences in COVID-19
title Sex-based clinical and immunological differences in COVID-19
title_full Sex-based clinical and immunological differences in COVID-19
title_fullStr Sex-based clinical and immunological differences in COVID-19
title_full_unstemmed Sex-based clinical and immunological differences in COVID-19
title_short Sex-based clinical and immunological differences in COVID-19
title_sort sex-based clinical and immunological differences in covid-19
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256650/
https://www.ncbi.nlm.nih.gov/pubmed/34225644
http://dx.doi.org/10.1186/s12879-021-06313-2
work_keys_str_mv AT huangbin sexbasedclinicalandimmunologicaldifferencesincovid19
AT caiyun sexbasedclinicalandimmunologicaldifferencesincovid19
AT lining sexbasedclinicalandimmunologicaldifferencesincovid19
AT likening sexbasedclinicalandimmunologicaldifferencesincovid19
AT wangzhihua sexbasedclinicalandimmunologicaldifferencesincovid19
AT lilu sexbasedclinicalandimmunologicaldifferencesincovid19
AT wulingxiang sexbasedclinicalandimmunologicaldifferencesincovid19
AT zhumengyan sexbasedclinicalandimmunologicaldifferencesincovid19
AT lijie sexbasedclinicalandimmunologicaldifferencesincovid19
AT wangziyu sexbasedclinicalandimmunologicaldifferencesincovid19
AT wumin sexbasedclinicalandimmunologicaldifferencesincovid19
AT liwanlin sexbasedclinicalandimmunologicaldifferencesincovid19
AT wuwei sexbasedclinicalandimmunologicaldifferencesincovid19
AT zhanglishen sexbasedclinicalandimmunologicaldifferencesincovid19
AT xiaxinyi sexbasedclinicalandimmunologicaldifferencesincovid19
AT wangshukui sexbasedclinicalandimmunologicaldifferencesincovid19
AT chenhongshan sexbasedclinicalandimmunologicaldifferencesincovid19
AT wangqianghu sexbasedclinicalandimmunologicaldifferencesincovid19